Small Molecules

11 Sep 2017 First Patients Enrolled in UK’s Early Access to Medicines Scheme for Santhera’s Raxone® in Duchenne Muscular Dystrophy (DMD)
10 Sep 2017 Combination of Lenvatinib and Pembrolizumab Results in Notable Response Rates for Patients with Advanced Renal Cell Carcinoma Based on Interim Analysis of Ongoing Phase 1b/2 Trial
10 Sep 2017 Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
10 Sep 2017 Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress
10 Sep 2017 Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017
09 Sep 2017 Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress
09 Sep 2017 AstraZeneca’s Tagrisso shows potential as a new standard of care in 1st-line EGFR-mutated lung cancer at ESMO 2017 Congress
08 Sep 2017 BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress
08 Sep 2017 Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy
08 Sep 2017 Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
08 Sep 2017 Boehringer Ingelheim is initiating Phase IIa study for the development of a new treatment for diabetic retinopathy – a leading cause of vision-loss
07 Sep 2017 Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
07 Sep 2017 Forge Therapeutics And Evotec Present Efficacy Data For LpxC Inhibitor In Urinary Tract, Lung, Thigh, And Abdominal Infection Models At ASM ESCMID 2017
07 Sep 2017 Adamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
07 Sep 2017 AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
07 Sep 2017 Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek
07 Sep 2017 Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
07 Sep 2017 Duaklir significantly improves lung function in COPD patients
06 Sep 2017 Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis
06 Sep 2017 Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
06 Sep 2017 Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
06 Sep 2017 Voyager Therapeutics Announces Positive Results from Ongoing Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
06 Sep 2017 ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
06 Sep 2017 Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
06 Sep 2017 Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing